Cancer-associated DNA hypomethylation is as prevalent as cancer-linked hypermethylation, but the biological significance of DNA hypomethylation in carcinogenesis is less understood. The expression of Maspin (mammary serpin) in differentiated normal cells is regulated by epigenetic modifications in a cell-type-specific manner. Paradoxical Maspin expression due to epigenetic modification has been addressed in several cancer cell types. To elucidate the role of the Maspin gene in thyroid cancer, we studied methylation status in the promoter region and its expression in six human undifferentiated thyroid cancer cell lines and in specimens from 92 primary thyroid tumors, consisting of six follicular adenomas, 56 welldifferentiated thyroid cancers (WDTCs), 17 poorly differentiated thyroid cancers (PDTCs) and 13 undifferentiated thyroid cancers (UDTCs). Three of the six cell lines overexpressed Maspin mRNA and its protein product, but the remaining three did not. The methylation status at the promoter region was inversely correlated with Maspin expression. In Maspin-negative cell lines, Maspin expression was induced by treatment with 5-aza-2 0 -deoxycytidine, a DNA demethylating agent. Immunoreactivity for Maspin protein was frequently detected in UDTCs (8/13, 62%) and PDTCs (7/17, 41%). Immunoreactivity for Maspin was diffusely positive in UDTCs, and was restricted to dedifferentiated components of the tumor in PDTCs. Positive immunoreactivity was infrequent in WDTCs (1/56, 2%), and all follicular adenomas and normal thyroid glands were completely negative. Their methylation status evaluated by the methylation-specific PCR method showed a good inverse correlation with their immunoreactivity in surgically resected specimens. Our data suggest that overexpression of Maspin by DNA hypomethylation is closely associated with morphological dedifferentiation in thyroid cancers.
Introduction
The 42-kDa protein Maspin (mammary serpin), a member of the serine protease inhibitor superfamily (Zou et al., 1994) , is a unique tumor suppressor because of its biological behavior and function. It has recently been reported that Maspin expression is downregulated during progression of breast, prostate and oral carcinomas (Zou et al., 1994; Sheng et al., 1996; Xia et al., 2000) . This finding is consistent with the fact that Maspin can act as a negative regulator of cell proliferation and survival, as cancer cells tend to have an increased proliferation rate and a reduced sensitivity to apoptosis . Other recent investigations have demonstrated that frequent silencing of Maspin expression occurs in breast cancer cell lines (Domann et al., 2000; Futscher et al., 2002) . In all cell lines in which Maspin expression was downregulated, Maspin promoter regions were hypermethylated and its expression was restored by treatment with a demethylating agent (Domann et al., 2000; Futscher et al., 2002) . These findings support the notion that hypermethylation of CpG island loci influences cancer progression. However, a few reports have described that Maspin was overexpressed in pancreatic and ovarian cancers, and that Maspin transcripts were negative in the corresponding normal tissues (Maass et al., 2001; Sood et al., 2002) . Thus, paradoxical Maspin protein expression due to epigenetic modification (hyper-or hypomethylation) has been described among various cancer cell types, making it difficult to understand the biological behavior of Maspin as a tumor suppressor. Futscher et al. (2002) have demonstrated that Maspin expression of normal cells is regulated by epigenetic modifications in a cell-type-specific manner. Their report provides an important insight into the controversial issue of whether DNA methylation controls tissue-specific gene expression. Maspin-positive epithelial cells (airway, breast, skin and prostate) showed no methylation at CpG islands in the Maspin promoter region (Futscher et al., 2002) . By contrast, Maspinnegative cells (skin fibroblast, lymphocytes, heart, liver and bone marrow) showed extensive methylation. Thus, cell-type-specific expression of Maspin is inversely correlated with the methylation status of the Maspin promoter (Futscher et al., 2002) . This cell-type-specific regulation mechanism in differentiated cell types may contribute to paradoxical Maspin expression among cancers.
It has been suggested that extensive DNA hypomethylation precedes cancer-linked DNA hypermethylation (Feinberg and Vogelstein, 1983; Gama-Sosa et al., 1983) . DNA hypomethylation in cancer often affects more of the genome than does hypermethylation, so that net losses of genomic 5-methylcytosine are seen in many human cancers (Gama-Sosa et al., 1983) . In an experimental analysis of DNA methyltransferase-deficient mice, Jaenisch and colleagues recently demonstrated that DNA hypomethylation plays a causal role in tumor formation, possibly by promoting chromosomal instability Gaudet et al., 2003) . The role of cancer-linked DNA hypomethylation is drawing more attention in cancer research (Ehrlich, 2002; Ehrlich et al., 2002) .
We recently reported that Maspin protein is selectively observed at high levels in gastric cancer cells as well as normal epithelium with intestinal metaplasia, but not in gastric normal epithelium without intestinal metaplasia (Akiyama et al., in press ). Demethylation on the haploid allele of the Maspin promoter produces abundant protein expression in Maspin-positive gastric cancer cells and normal epithelium with intestinal metaplasia. Moreover, the extent of hypomethylation of the Maspin gene promoter is greater in gastric cancers. These data suggest that demethylation at the Maspin gene promoter region disrupts the cell-typespecific gene repression of the establishment and/or maintenance of differentiated gastric normal epithelia, and may contribute to the development of intestinal metaplasia and/or gastric carcinogenesis (Akiyama et al., in press ).
Epigenetic modifications involving several tumorrelated genes have been examined in thyroid tumor cells (Matsuo et al., 1993) . Aberrant methylations in tumorrelated genes (c-myc, p16, p15, RASSF1A, E-cadherin, PTEN and sodium-iodide symporter) accumulate in thyroid cancer cells (del Senno et al., 1987; Berlingieri et al., 1989; Elisei et al., 1998; Graff et al., 1998; Venkataraman et al., 1999; Frisk et al., 2002; Schagdarsurengin et al., 2002) . Epigenetic changes are an important mechanism underlying the progression of thyroid cancer, but the methylation status of the Maspin gene and the expression of its transcript in normal thyroid glands and thyroid neoplasms have never been systematically examined. To clarify the significance of Maspin in thyroid tissues and neoplasms, we assessed Maspin expression and/or epigenetic status in a series of six thyroid cancer cell lines and 92 cases of thyroid neoplasms, including six thyroid adenomas. We found that aberrant expression of Maspin related to hypomethylation status of the promoter region was closely associated with morphological dedifferentiation of thyroid cancer cells.
Results

Maspin expression and methylation status of thyroid cancer cell lines
Expression of maspin was investigated in human thyroid cancer cell lines established from undifferentiated thyroid cancers (UDTCs) by means of Western blot and real-time quantitative PCR (RQ-PCR) analyses. Maspin was strongly expressed in KHM-5M, HTC/C3 and 8505C, whereas its expression was not detected in the other three cell lines (8305C, HOTHC and TCO-1) ( Figure 1a ). Maspin mRNA was detectable in KHM-5M, HTC/C3 and 8505C ( Figure 2 and Table 1 ), but no amplification of Maspin mRNA was found in 8305C, HOTHC and TCO-1. Maspin protein expression of the three cell lines, 8305C, HOTHC and TCO-1, was induced after treatment with the demethylation agent, 5-aza-2 0 -deoxycytidine (5-aza-dC) (Figure 1b ). There was a similar effect on Maspin mRNA (Table 1 ). These data suggest that demethylation at the Maspin promoter induces expression of its mRNA and protein.
We examined the methylation status of the Maspin promoter in six cell lines. The results of sodium bisulfite genomic sequence analysis are shown in Figure 3 . The three Maspin-positive cell lines (KHM-5M, HTC/C3 and 8505C) showed extensive hypomethylation, and two of the Maspin-negative cell lines (TCO-1 and HOTHC) were hypermethylated. Demethylation at 19 CpG sites occurred randomly in one Maspin-negative cell line (8305C). All sequences of subclones showed an identical methylation pattern in TCO-1. HTC/C3 contained two major clones. We found a single-nucleotide polymorphism (SNP) site in the sequenced region (A/C at À156, where the number indicates the site location from the (Figure 3a, b) . We found that the demethylation of HTC/C3 occurred allele specifically. A few minor clones were found in KHM-5M, 8505C and 8305C, but we could not determine whether these variations among the sequenced subclones occurred allele specifically or because of other factors (for example, effects of long-term culture or PCR error) (Figure 3c ).
Immunohistochemical staining for Maspin in thyroid neoplasms and normal tissues
The expression of Maspin protein in surgical specimens of thyroid neoplasms and normal tissues was studied by immunohistochemistry. Staining results are summarized in Table 2 . Immunoreactivity of all normal thyroid tissues ( Figure 4a ) surrounding thyroid neoplasms and follicular adenomas (Figure 4b ), as well as in normal thyroid tissues obtained from five autopsy cases, was completely negative. Almost all well-differentiated thyroid cancers (WDTCs) did not stain ( Figure 4c , Table 2 ), whereas the single WDTC (1/56, 2%) that showed positive staining was stained only in a restricted area of the tumor (Figure 4d , e). This tumor was diagnosed as a rare type of papillary carcinoma, the diffuse sclerosing variant. Maspin-positive staining was restricted to portions exhibiting squamous metaplasia (Figure 4d , e). Some lesions exhibiting a solid or squamous appearance showed positive immunoreactivity in seven (41%) of 17 poorly differentiated thyroid cancers (PDTCs) (Figure 5a , b, Table 2 ), whereas no immunoreactivity was observed in their WDTC component ( Figure 5b ). In terms of subcellular localization, staining for Maspin protein was generally observed in the cytoplasm, and nuclear localization was extremely rare. Furthermore, eight (62%) of 13 UDTCs demonstrated diffuse cytoplasmic staining for Maspin ( Figure  5c , d, Table 2 ).
Methylation-specific PCR of Maspin in thyroid neoplasms and normal tissues
By the methylation-specific PCR (MSP) method, we evaluated the promoter status at the Maspin gene in 92 thyroid neoplasms and matching normal thyroid tissues, and five normal thyroid glands obtained from autopsy cases. In six UDTC cell lines, our MSP primer sets were able to correctly distinguish their methylation status at the Maspin promoter compatible with sequencing results and protein expression ( Figure 6a ). We also tested the primer sets in a series of 24 human malignant tumor cell lines (four gastric cancer, 10 hepatocellular carcinoma, eight colonic cancer and two osteosarcoma cell lines). Some of them (for example, a gastric cancer cell line, MKN74, shown in Figure 6a ) showed that demethylation occurs allele specifically on the haploid allele. In these tumors, both the methylated (M)-and ummethylated (U)-primer sets produced a positive signal ( Figure 6a ). We had previously confirmed that demethylation of the haploid allele produces abundant protein expression in Maspin-positive gastric cancer cell lines and normal epithelium. This type of tumor was judged to be an unmethylated tumor.
PCR was successful for an M-primer set in normal tissues of all 92 thyroid neoplasms and five autopsy cases ( Figure 6b ). No positive signal was observed when using a U-primer set ( Figure 6b , Table 2 ). In all of six follicular adenomas and 56 WDCTs, 12 of 17 PDTCs and five of 13 UDTCs, positive signals were not observed for a U-primer set, but were observed for an M-primer set ( Figure 6b , Table 2 ). Immunoreactivity for Maspin was negative in these tumors. Eight of 13 UDTCs produced positive signals for both M-and Uprimer sets ( Figure 6c , Table 2 ). This might have been due to contamination by nontumor cells, or to different methylation status of the alleles. Immunoreactivity for Maspin was positive in these eight UDTCs. For seven PDTCs with Maspin-positive staining and the diffuse sclerosing variant of WDTC, we tried microdissection to (Figure 6c ). Methylation status judged from MSP primer sets showed a good inverse correlation with immunohistochemical staining results (Po0.01, Table 3 ).
Discussion
In this study, we demonstrated that demethylation at the Maspin promoter upregulated the expression of its protein in thyroid cancer cell lines and primary thyroid cancers. Moreover, aberrant Maspin expression was frequently observed in UDTCs and in dedifferentiated components of PDTCs. The only Maspin-positive case among the WDTCs was an example of the diffuse -3) , autopsy cases (lanes 4-6) and WDTCs (lanes 7-9). Lane 11 was a positive control for the M-primer set (HOTHC) and lane 10 was a positive control for the U-primer set (KHM-5M). A faint band was observed in lane 11 (positive control for the U-primer set). We had to increase the number of PCR cycles because the DNAs obtained from formalin-fixed samples exhibited lower integrity than those of the cell lines. The faint signal may have been MSP noise due to the increased number of PCR cycles. No positive signal was observed by using an U-primer set in lanes 1-9. (c) PCR was successful with a U-primer set in PDTCs (lanes 1-5) and UDTCs (lanes 6-9). Microdissection was performed to separate PDTC components from WDTC and normal parts of surgical specimens. Three of the five PDTCs produced positive signals only with a U-primer set and the remaining two did so for both primer sets. UDTCs produced positive signals for both Mand U-primer sets. Lane 11 was a positive control for the M-primer set (HOTHC) and lane 10 was a positive control for the U-primer set (KHM-5M) sclerosing variant of thyroid cancer, which differs from classical papillary carcinoma not only in histological appearance but also in its clinical course: younger age at presentation, greater incidence of lymph node and lung metastasis, and lower disease-free survival on follow-up (Hedinger et al.; Rosai et al.) . Our data suggest that aberrant Maspin expression is induced by demethylation at the promoter region and is closely related to the dedifferentiated morphological phenotype of tumor cells. Domann and colleagues showed that Maspin expression is governed by the methylation status of its CpG island, and that Maspin-nonexpressing normal cells have completely methylated CpG islands, resulting in transcriptional repression (Domann et al., 2000; Futscher et al., 2002) . They concluded that CpG methylation is important for the establishment and maintenance of cell-type-restricted gene expression. We examined methylation status at the Maspin promoter region in five normal thyroid glands obtained from autopsy cases, two benign follicular adenomas and two WDTCs by using sodium bisulfite genomic sequence analysis. All of them showed extensive hypermethylation at the promoter regions (data not shown). In normal thyroid glands, Maspin expression is repressed, in order to maintain cellular differentiation, by the celltype-specific methylation mechanism (Futscher et al., 2002) . It is easy to understand that this mechanism is preserved in benign neoplasms and WDTCs; in contrast, disruption of the mechanism is frequently observed in tumors exhibiting morphological dedifferentiation. Maass et al. (2001) reported that Maspin could be detected immunohistochemically in five of nine pancreatic cancer cell lines and 23 of 24 tumor surgical specimens, but was not detected in normal pancreatic tissues. Sood et al. (2002) demonstrated Maspin immunoreactivity in 57 (71%) of 80 invasive ovarian tumors. Although the methylation status of the Maspin promoter was not evaluated in either report, the same mechanism for aberrant Maspin expression presumably occurred. The functional significance of aberrant Maspin expression in cancer cells has remained unclear. However, we recently found that demethylation on the haploid allele was sufficient to produce abundant Maspin protein in gastric mucosa with intestinal metaplasia, which might be a precancerous lesion of gastric cancer (Akiyama et al., in press ). Moreover, the unmethylated status of the Maspin gene promoter was more pronounced in gastric cancers. In the present study, positive immunoreactivity was restricted to the solid or squamous component of PDTCs, squamous metaplasia in the diffuse sclerosing variant of papillary carcinoma, and UDTCs. Aberrant expression of Maspin protein has also been described in precancerous lesions of the pancreas and ovary (Maass et al., 2001; Sood et al., 2002) . These data lead us to speculate that demethylation at the Maspin gene promoter may play a central role in disruption of the Maspin-regulation mechanism and contribute to the transformation of normal differentiated cells to metaplastic or dysplasic cells in several organs.
Recent epigenetic studies have shown that the silencing of tumor-related genes by hypermethylation might play an important role in the development of thyroid cancer (Elisei et al., 1998; Graff et al., 1998; Schagdarsurengin et al., 2002) . There has been no report indicating that hypomethylation may affect the expression of tumor suppressor genes and thus contribute to the tumorigenesis of thyroid cancers. Recently, Jaenisch and colleagues Gaudet et al., 2003) demonstrated that DNA hypomethylation plays a causal role in tumor formation, possibly by promoting chromosomal instability. Several lines of evidence suggest that follicular cells derived from thyroid cancers represent a continuum of disease that progresses from the highly curable WDTC to the universally fatal anaplastic cancers (or UDTC). Wreesmann et al. (2002) reported that chromosomal instability accelerated the continuum process. Both chromosomal instability and DNA hypomethylation are presumably related to dedifferentiation of thyroid cancer progression.
Until now, the function of the Maspin gene has been considered to be tumor suppression (Zou et al., 1994; Seftor et al., 1998; Abraham et al., 2003) . However, Maspin seems to behave as an oncogene rather than a tumor suppressor gene in pancreatic, ovarian and thyroid cancers (Maass et al., 2001; Sood et al., 2002) . Sood et al. (2002) demonstrated that patients with invasive ovarian cancers exhibiting Maspin upregulation had worse prognoses, whereas there has been no functional evidence to suggest that overexpression of Maspin contributes to the acquisition of malignant behavior in these tumor types. We have not yet demonstrated that Maspin-positive thyroid cancers have a worse prognosis than Maspin-negative cases. Further studies are needed to clarify the functional significance of Maspin overexpression in thyroid cancers, and why demethylation at the CpG islands of the Maspin promoter occurs in restricted types of tumors.
Materials and methods
Cell culture
Six UDTC cell lines (HOTHC, HTC/C3, 8505C, 8305C, KHM-5M and TCO-1) were maintained under their recommended conditions. HOTHC (developed by Dr I Ishiwata at Ishiwata Obstetrics and Gynecologic Hospital, Mito, Japan) (Ishiwata et al., 1999) and HTC/C3 (developed by Dr H Sugawa at Sugawa Clinic, Kyoto, Japan) (Yoshimoto et al., 1992) were obtained from the RIKEN cell bank (Tsukuba, Japan). Lines 8505C and 8305C were provided by the Cell Resource Center for Biomedical Research, Tohoku University (Sendai, Japan) (Ito et al., 1992; Yoshimoto et al., 1992) . KHM-5M (cell number JCRB0148; developed by Drs H Matsuzaki and K Takatsuki) (Yoshida et al., 1992) and TCO-1 (cell number JCRB0239; developed by Dr S Takai) (Yoshimoto et al., 1992) were obtained from the Health Science Research Resource Bank (Osaka, Japan).
Treatment with 5-aza-dc
Cells were seeded at a density of 5 Â 10 5 cells/10-cm plate on day 1. After 24 h, 5-aza-dC (Sigma, St Louis, MO, USA) was added to a final concentration of 10 mM. At 3 days after 5-azadC treatment, the cells were harvested for Western blotting and RQ-PCR.
Surgical specimens and DNA extraction
Tumor specimens were obtained from 92 patients with primary thyroid neoplasms who underwent thyroidectomy between 1984 and 2001 at the Department of Surgery 1 (Iwate Medical University School of Medicine, Morioka, Japan). Our subjects comprised 25 males and 67 females (mean age; 47.9 years, range; 18-89 years). The specimens comprised six follicular adenomas, 56 WDTCs (conventional types of papillary or follicular carcinomas, including one case of the diffuse sclerosing variant), 17 PDTCs (papillary or follicular carcinomas with a solid, trabecular or scirrhous growth pattern) and 13 UDTCs (anaplastic cancer). All the samples were reviewed by at least two pathologists to confirm the diagnoses.
Permission for the study was obtained from the Institutional Review Board (IRB) of Iwate Medical University School of Medicine, Morioka, Japan.
DNA was extracted from microdissected materials of paraffin-embedded specimens using an EX-WAX TM DNA Extraction Kit (Intergen, Purchase, NY, USA).
Western blotting
The cell suspension was centrifuged at 7500 r.p.m. for 1 min. After removal of the supernatants, the cell pellet was dissolved in 1.0% NP-40 lysis buffer (50 mM HEPES (pH 7.5)/1 mM EDTA/150 mM NaCl/2.5 mM EGTA/1.0% NP-40). Cell samples containing equal amounts of protein were mixed with 6 Â concentrated loading dye, heated for 4 min at 951C, and subjected to SDS-PAGE on a 10% polyacrylamide gel (BioRad Laboratories, Hercules, CA, USA). The proteins were then transferred to a PVDF membrane (Amersham Biosciences, Buckinghamshire, UK) by electroblotting. Primary monoclonal antibody for Maspin (anti-human Maspin antibody; Pharmingen International, San Diego, CA, USA) was diluted 1 : 5000 in 0.05% Tween-20 PBS. The membrane was incubated for 1 h at room temperature and washed. For the second antibody, anti-mouse IgG (Amersham Pharmacia) was diluted 1 : 10000 in blocking buffer. The membrane was then incubated for 45 min at room temperature and washed. Maspin protein was detected by ECL Plus (Amersham Pharmacia).
Real-time quantitative PCR
In the RQ-PCR assay, primers and a fluorogenic probe were designed with Primer Express software (ABI): Maspin F (nt 646-665; 5 0 -CGA CCA GAC CAA AAT CCT TG-3 0 ), Maspin R (nt 778-796; 5 0 -GAA CGT GGC CTC CAT GTT C-3 0 ), probe (nt 745-772; 5 0 -FAM-CAA CAA GAC AGA CAC CAA ACC AGT GCA G-TAMURA-3 0 ). The RQ-PCR assay used the ABI PRISM 7700 Sequence Detector (ABI). The reaction mix contained 50 ng of cDNA, 200 nmol/l each primer, 5 mM probe, and 25 ml of TaqMan Universal PCR Master Mix (ABI) in a final volume of 50 ml. The cDNA was subjected to 50 cycles of a two-step PCR consisting of a 15-s denaturation step at 951C and a 1-min combined annealing/ extension step at 601C. Plasmids were diluted in a precise series, ranging from 5 pg to 0.005 fg (2 Â 10 6 to two copies). For normalization of each target in the samples, the copy number of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The normalized values of Maspin mRNA were expressed as the ratio of maspin copy number per 10 3 copy number of GAPDH.
Methylation assay
DNAs obtained from cell lines were treated with bisulfite modification and examined for the methylation status of 19 CpG dinucleotides within the Maspin gene promoter region (Zhang et al., 1997; Domann et al., 2000) . Genomic DNA was digested by PstI and then subjected to bisulfite modification as described previously (Clark et al., 1994) . Briefly, 1 mg of genomic DNA was denatured by treatment with NaOH and modified by sodium bisulfite. Samples were then purified by the use of Wizard DNA purification resin (Promega Corp., Madison, WI, USA), treated again with NaOH, precipitated with ethanol and resuspended in water. Modified DNA was PCR-amplified under conditions described previously (Futscher et al., 2002) . The Maspin gene promoter was amplified from the bisulfite-modified DNA by two rounds of PCR using nested primers specific to the bisulfite-modified sequence of the Maspin gene CpG island. 0 . Both rounds of PCR were performed under the same conditions, with 1% of the first round PCR product serving as the template in the second round. PCR amplification was performed under the following conditions: 941C for 4 min followed by five cycles of 941C for 1 min, 561C for 2 min, 721C for 3 min, then 35 cycles of 941C for 30 s, 561C for 2 min, 721C for 1.5 min and ending with a final extension of 721C for 6 min. Amplified PCR products were analysed by electrophoresis on a 2% agarose gel. PCR products were purified with a QIAquick Gel Extraction Kit (QIAGEN). The PCR fragments were ligated to pGEM-T Easy Vectors (Promega) and transformed into DH5a competent cells (TOYOBO, Tokyo, Japan). In all, 10 subcloned colonies were chosen at random from each thyroid cancer cell line. Plasmid DNA was purified by a PI-200 DNA automatic isolation system (KURABO, Osaka, Japan). Cycle sequencing used a BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (Applied Biosystems; ABI, Foster City, CA, USA) and ABI PRISM 3100 DNA Sequencer (ABI).
For analysis of the methylation status of surgical specimens, we used MSP method. DNAs extracted from microdissected materials were treated with CpGenome TM DNA Modification Kit (Intergen). Two sets of primers were designed to specifically amplify either the methylated (M) (M94F: ATT TTT ATT TTA TCG AAT ATT TTA TTT TTC GGT/ M173R: TAC ATA CGT ACA AAC ATA CGT ACG ACA ATC CTC TCG) or unmethylated (U) (U93F: TAT TTT TAT TTT ATT GAA TAT TTT ATT TTT TGG T/U173R: TAC ATA CAT ACA AAC ATA CAT ACA ACA ATC CTC TCA) bisulfite-modified sequence, by using the MethPrimer program (http://www.methdb.de). Modified DNA was amplified using the same method of first round PCR as that used in the bisulfite genome sequencing method. The second round PCR was performed using 1 ml of the first round product, 25 ml of Aplitic Gold PCR Master Mix (ABI), and 200 nmol/l each primer in a final volume of 50 ml. PCR amplification was performed under the following conditions: 951C for 5 min followed by five cycles of 951C for 30 s, 641C for 2 min, five cycles of 951C for 30 s, 621C for 2 min, then 30 cycles of 951C for 15 s, 601C for 1 min and ending with a final extension of 721C for 6 min.
Immunohistochemical staining
Slices of 4-mm thickness slices were cut from formalin-fixed, paraffin-embedded samples and stained with hematoxylin and eosin. Serial sections were stained immunohistochemically. After deparaffinization and antigen recovery, the sections were washed in PBS (3 Â 5 min) and immersed in 0.3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity. After washes with PBS (3 Â 5 min), the sections were incubated with 5% bovine serum albumin for 10 min to block nonspecific reactions. Then the sections were incubated overnight at 41C with anti-human Maspin antibody (dilution 1 : 50). Secondary antibody and peroxidase labeling were performed with a Simple Stain MAX-PO kit (Nichirei, Tokyo, Japan), colorization was produced by DAB substrate (Dako) for 2 min, and counterstaining was performed with Mayer's hematoxylin.
Statistical analysis
Correlation of immunohistochemical and MSP analyses for Maspin was evaluated with Fisher's exact test. Differences at Po0.05 were considered significant.
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